Valuation: Bicycle Therapeutics plc

Market Cap 294M 258M 238M 221M 417M 27.94B 426M 2.86B 1.11B 13.72B 1.1B 1.08B 47.73B P/E 2026 *
-1.81x
P/E 2027 * -2x
Enterprise Value -218M -191M -176M -164M -310M -20.73B -316M -2.12B -821M -10.18B -819M -801M -35.42B EV / Sales 2026 *
-12x
EV / Sales 2027 * -7.81x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.71%
1 week+6.31%
Current month-0.71%
1 month-7.06%
3 months-14.08%
6 months-40.54%
Current year-40.54%
1 week 3.98
Extreme 3.985
4.34
1 month 3.92
Extreme 3.92
4.38
Current year 3.92
Extreme 3.92
7.34
1 year 3.92
Extreme 3.92
9.18
3 years 3.92
Extreme 3.92
28.67
5 years 3.92
Extreme 3.92
62.08
10 years 3.92
Extreme 3.92
62.08
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2015
Director of Finance/CFO 46 28/01/2026
Chief Tech/Sci/R&D Officer - 31/05/2025
Director TitleAgeSince
Director/Board Member 57 31/08/2015
Director/Board Member 63 16/03/2021
Director/Board Member 69 19/02/2024
Date Insider Type Main position Quantity % Market Cap.
04-01Sell

Chief Operating Officer

1,408 0.0037%
04-01Sell

Chief Executive Officer

7,683 0.0202%
04-01Sell

CHIEF PROD & SUPPLY CHAIN OFF

1,772 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%+6.31%-40.11%-83.50% 296M
-2.19%+6.01%+66.90%+123.30% 57.65B
+0.55%+8.49%+77.09%+100.93% 55.14B
+0.93%+4.11%-12.64%-12.98% 23.53B
+0.36%+3.42%+9.61%+407.11% 23.11B
-1.93%+6.66%+34.89%-7.86% 18.14B
+0.28%+5.51%+36.93%-30.23% 16.84B
-0.83%+2.06%+23.70%+182.37% 13.68B
+0.14%+3.27%+33.31% - 12.97B
-4.20%+0.91%+71.37%+122.68% 12.38B
Average -0.76%+3.61%+30.11%+89.09% 23.37B
Weighted average by Cap. -0.67%+3.78%+46.70%+113.75%

Financials

2026 *2027 *
Net sales 18.24M 16.01M 14.74M 13.73M 25.9M 1.73B 26.42M 177M 68.68M 851M 68.47M 66.99M 2.96B 14.11M 12.39M 11.41M 10.63M 20.04M 1.34B 20.45M 137M 53.15M 659M 52.99M 51.84M 2.29B
Net income -154M -135M -124M -116M -218M -14.61B -223M -1.49B -579M -7.17B -577M -564M -24.96B -162M -143M -131M -122M -231M -15.43B -235M -1.58B -611M -7.58B -610M -596M -26.36B
Net Debt -512M -450M -414M -386M -727M -48.68B -742M -4.98B -1.93B -23.89B -1.92B -1.88B -83.15B -404M -355M -327M -304M -574M -38.42B -586M -3.93B -1.52B -18.86B -1.52B -1.48B -65.64B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
01/07/26 US$4.210 -0.71% 321,965
30/06/26 US$4.240 +2.17% 428,207
29/06/26 US$4.150 +1.22% 783,600
26/06/26 US$4.100 +2.24% 843,360
25/06/26 US$4.010 +1.26% 504,336
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.210USD
Average target price
12.62USD
Spread / Average Target
+199.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock